Dr. Sarah Chen
J.P. Morgan
Michael Patel
Goldman Sachs
Emily Rodriguez
Morgan Stanley
Firms providing research coverage.
Top-tier financial institutions tracking our progress in radiopharmaceutical innovation.
Strong Buy rating reflects confidence in our clinical execution, manufacturing scale-up, and market potential in targeted radiotherapeutics.
Important Disclosure: Analyst ratings and target prices are independent opinions and do not represent Medisafe Therapeutics' views. The company is not responsible for the content of third-party research. For official guidance, refer to SEC filings and earnings releases.
Schedule a call, request materials, or join our next earnings webcast.